Table 5 (A) Baseline and LSM change and (B) LSM differences in change from baseline in the EQ-5D HSI and EQ-5D VAS scores by severity level of skin toxicity in the first- and second-line trials
(A) | ||||
|---|---|---|---|---|
First-line trial | Second-line trial | |||
Severity level of skin toxicities | EQ-5D HSI | EQ-5D VAS | EQ-5D HSI | EQ-5D VAS |
None/mild | ||||
Baseline | 0.733 | 73.6 | 0.751 | 71.9 |
LSM change | −0.001 | 1.7 | −0.076 | −3.3 |
Moderate | ||||
Baseline | 0.780 | 73.9 | 0.783 | 73.0 |
LSM change | 0.041 | 2.9 | 0.001 | −0.7 |
Severe | ||||
Baseline | 0.794 | 74.5 | 0.772 | 74.1 |
LSM change | 0.016 | −0.5 | −0.019 | −1.6 |
(B) | ||||
First-line trial | Second-line trial | |||
Difference between groups | EQ-5D HSI | EQ-5D VAS | EQ-5D HSI | EQ-5D VAS |
Moderate vs none/mild | 0.042 | 1.206 | 0.077 | 2.571 |
(95% CI) | (−0.012, 0.095) | (−3.309, 5.720) | (0.014, 0.140) | (−1.645, 6.786) |
Severe vs none/mild | 0.017 | −2.261 | 0.056 | 1.698 |
(95% CI) | (−0.038, 0.071) | (−6.869, 2.347) | (−0.003, 0.116) | (−2.349, 5.746) |
